Tusi
pink cocaine · tuci · tucibi
What does current UK evidence show?
Products analysed in the UK and Europe commonly contain ketamine combined with stimulant drugs, particularly MDMA and/or caffeine, although composition varies considerably. Despite the names ‘pink cocaine’ and ‘tucibi’, products may contain neither cocaine nor 2C-B.
Overview
Identity, legal classification, form and pharmacological context
- Drug category
- Synthetic drugs · Stimulants · Dissociatives
- Common names
- pink cocaine, tuci, tucibi
- Typical forms
- Brightly coloured, often pink, powder. Colour, branding and sold name cannot establish the contents
- Routes
- Most commonly snorted; it may also be swallowed. The route and composition may be uncertain
- UK legal classification
- Contents-dependentTusi is not one substance; legal classification depends on the controlled drugs found in the mixture.Check government source ↗
- Concise pharmacology
- There is no single Tusi pharmacology. Effects reflect the mixture present and may combine ketamine-related dissociation with MDMA or caffeine-related stimulant and serotonergic effects.
Main harms
Concise clinical and polydrug picture
Effects vary with the mixture and may include stimulation, dissociation, agitation, overheating, vomiting, reduced consciousness or serotonin toxicity.
Longer-term harms depend on the substances and pattern of use; repeated ketamine exposure can cause severe bladder and urinary-tract injury.
Dependence and withdrawal depend on the ingredients and frequency of use; a single fixed syndrome should not be assumed.
Unknown or changing contents make interactions difficult to predict. Alcohol, sedatives and additional stimulants can compound toxicity.
Snorting can damage nasal tissue. Uneven mixing, uncertain potency and mis-selling make dose difficult to judge.
Current intelligence status
Assessment, confidence and direction
Products analysed in the UK and Europe commonly contain ketamine combined with stimulant drugs, particularly MDMA and/or caffeine, although composition varies considerably. Despite the names ‘pink cocaine’ and ‘tucibi’, products may contain neither cocaine nor 2C-B.
Reason: Sparse or selected evidence supports only this narrow assessment; the wider market and trend remain uncertain.
Principal source limits: Draws on UK and international evidence; surveillance coverage and reporting periods vary by dataset. Submitted samples confirm their own contents but cannot estimate prevalence or represent the wider drug supply.
Geography and reference periods are given in each linked source card below. The rating is an editorial evidence judgement, not a probability, clinical risk score or TD priority.Available UK evidence is too limited or unrepresentative for a stronger trend judgement.
Operational implications
Evidence-supported prompts for professional response
Use contents-first alerts, promote analytical confirmation and avoid presenting a single sample as representative of the market.
Record substance, sold identity, route, frequency and combinations; review physical, mental-health and dependence needs.
Use symptom-led assessment and escalate reduced consciousness, seizures, overheating, chest pain or severe agitation.
Send unexpected products or incidents through agreed testing and alert routes; distinguish confirmed results from preliminary reports.
Related intelligence
Continue into connected platform evidence
Sources & limitations
Direct evidence links, reference periods and status
Ketamine: an updated review of use and harms
Published28 Jan 2026Reference periodEvidence reviewed to 2025
Draws on UK and international evidence; surveillance coverage and reporting periods vary by dataset.Welsh Emerging Drugs and Identification of Novel Substances
PublishedContinuousReference periodSubmitted samples
Submitted samples confirm their own contents but cannot estimate prevalence or represent the wider drug supply.